Back to top
more

Blueprint Medicines Corporation (BPMC)

(Real Time Quote from BATS)

$80.62 USD

80.62
270,636

+2.05 (2.61%)

Updated Aug 21, 2019 01:53 PM ET

Add to portfolio

4-Sell       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.58%
17.73%
9.37%
4.95%
1.76%
10.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark

Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

RHHBY ACOR BPMC RGEN

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -6.25% and 80.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BPMC

Zacks Equity Research

The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

VSTM INCY BPMC QURE

Zacks Equity Research

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

PFE QURE BPMC ARRY VSTM INCY

Zacks Equity Research

Blueprint Medicines (BPMC) Up 7.3% Since Last Earnings Report: Can It Continue?

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BPMC

Zacks Equity Research

Blueprint Medicines to File NDA for Avapritinib With FDA

Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.

PFE BAYRY RHHBY BPMC

Zacks Equity Research

Blueprint Medicines' NDA for Avapritinib on Track for GIST

Blueprint Medicines (BPMC) reports data on avapritinib from NAVIGATOR study for treating patients with PDGFRA Exon 18 mutant GIST and the fourth-line GIST.

RHHBY PFE BAYRY BPMC

Zacks Equity Research

Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates

Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.

RHHBY BPMC FCSC CLSN

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q1 Loss, Misses Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -8.20% and -75.67%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BPMC

Zacks Equity Research

Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

MRK PFE BPMC XLRN PDLI IONS GH

Zacks Equity Research

Earnings Preview: Blueprint Medicines (BPMC) Q1 Earnings Expected to Decline

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BPMC

Zacks Equity Research

Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session

Blueprint Medicines (BPMC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

BPMC CELG

Zacks Equity Research

Blueprint Medicines Expediates Filings for Key Candidates

Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.

PDLI CELG KMDA BPMC

Swarup Gupta

5 Cancer-Fighting Stocks to Boost Portfolio Gains

It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.

BMY BAYRY JNJ LLY GSK RHHBY BPMC CELG SNSS

Zacks Equity Research

Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BPMC

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.73% and -45.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

BPMC

Zacks Equity Research

Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BPMC

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 52.67% and 1199.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

BPMC

Zacks Equity Research

Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?

Intuitive Surgical (ISRG) is expected to witness growth across da Vinci Surgical and Service segments. Instruments and accessories revenues are also expected to increase year over year.

ISRG BPMC CNC EIGR

Zacks Equity Research

Company News For Dec 12, 2017

Companies in the news are: KMG,ARGX,BPMC,BLUE

KMG BLUE BPMC ARGX

Zacks Equity Research

Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session

Blueprint Medicines Corporation (BPMC) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

ENZ BPMC

Arpita Dutt

3 Biotech Stocks That Are Broker Favorites

These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).

AMGN BIIB CLLS BPMC

Zacks Equity Research

Can The Uptrend Continue for Blueprint Medicines (BPMC)?

Investors certainly have to be happy with Blueprint Medicines Corporation (BPMC) and its short term performance

BPMC

Zacks Equity Research

Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?

Investors are always looking for stocks that are poised to beat at earnings season and Blueprint Medicines Corporation (BPMC) may be one such company.

BPMC

Zacks Equity Research

Zimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?

Zimmer Biomet Holdings, Inc. (ZBH) is expected to report fourth-quarter 2017 financial numbers on Jan 31, before the opening bell.

BPMC CATB ZBH HSGX